New Cases Of Cancer Research Articles

New options for treatment of chronic pain syndrome

According to the World Health Organization, 12.6 million new cases of cancer were identified in 2008. In 2022, this number reached 18.1 million cases, and it is projected to increase to 26 million in 2040. Chronic pain is defined by the International Association for the Study of Pain as pain that persists or recurs for 3 months. A similar definition is given in the International Classification of Diseases, 11th revision, which for the first time includes chronic pain as an independent category with a unique code MG30. The incidence of pain syndrome in advanced terminal or metastatic stages of cancer is 64 %, during antitumor therapy – 59 %, after successful treatment – 33 %. However, side effects from opioids significantly worsen the quality of life of patients.A new type of peptide drugs can reduce the toxic effects of drug pain therapy.

The overwhelming problem of childhood cancer in Mexico

Childhood cancer is the second cause of mortality of the population between 4 and 15 years. More than 20 million new cases of cancer in the world are expected by the year 2025, and 80% of the load will be on countries of low to middle income. In the past two decades, significant changes have been observed in patterns of incidence, prevalence, survival, and childhood cancer mortality in Mexico. An extensive review of all the published studies in Mexico by various health institutions revealed a steady 18-year trend of 150 new cases/million/year. The prevalence showed that acute leukemias constitute a 50% of all childhood cancer cases, followed by lymphoma (Hodkin and non-Hodgkin), and primary malignant brain tumors. A significant survival rate was observed in 8 thousand children with acute lymphoblastic leukemia with an overall 5-year survival rate of 62%, with a range of 45 to 73%. The national mortality rate for all types of cancer was 5.2/100,000/year, which is higher than what is reported in most middle-income countries. In the face of the current results, the need arises to modify how we approach this group of diseases by integrating a socio-educational healthcare of the Mexican children who are currently treated under unfavorable conditions. The current sanitary authorities must be aware of the importance of the transmission and adjustment of the care received by children with these diseases at a national level, to be in line with international standards. KEYWORDS: Childhood Cancer, Morbidity, Mortality, leukemia, lymphoma

Spatial consistency of co-exposure to air and surface water pollution and cancer in China

Humans can be exposed to multiple pollutants in the air and surface water. These environments are non-static, trans-boundary and correlated, creating a complex network, and significant challenges for research on environmental hazards, especially in real-world cancer research. This article reports on a large study (377 million people in 30 provinces of China) that evaluated the combined impact of air and surface water pollution on cancer. We formulate a spatial evaluation system and a common grading scale for co-pollution measurement, and validate assumptions that air and surface water environments are spatially connected and that cancers of different types tend to cluster in areas where these environments are poorer. We observe “dose–response” relationships in both the number of affected cancer types and the cancer incidence with an increase in degree of co-pollution. We estimate that 62,847 (7.4%) new cases of cancer registered in China in 2016 were attributable to air and surface water pollution, and the majority (69.7%) of these excess cases occurred in areas with the highest level of co-pollution. The findings clearly show that the environment cannot be considered as a set of separate entities. They also support the development of policies for cooperative environmental governance and disease prevention.

Interpretation on the report of global cancer statistics 2022

In April 2024, the World Health Organization/International Agency for Research on Cancer (IARC) published the global cancer statistics 2022 in the CA: Cancer Journal for Clinicians. This report focuses on the incidence and mortality of 36 cancers in 185 countries or territories worldwide, analyzing the differences of gender, geographic region, and the Human Development Index (HDI) level. It is estimated that in the year 2022, there were 19.96 million new cancer cases and 9.74 million cancer deaths worldwide. Lung cancer (2 480 301, 12.4%) was the most frequently diagnosed cancer in 2022, followed by female breast cancer (2 295 686, 11.5%), colorectal cancer (1 926 118, 9.6%), prostate cancer (1 466 680, 7.3%), and gastric cancer (968 350, 4.9%). Lung cancer (1 817 172, 18.7%) was also the leading cause of cancer death, followed by colorectal cancer (903 859, 9.3%), liver cancer (757 948, 7.8%), female breast cancer (665 684, 6.9%), and gastric cancer (659 853, 6.8%). With demographics-based predictions indicating that the number of new cases of cancer will reach over 35 million by 2050. The Beijing Office for Cancer Prevention and Control team has collated this report and briefly interpreted it in combination with the current situation of cancer incidence and mortality in China.

Abstract PO5-27-08: Cytotoxicity and motility inhibitory effect of FA-Hep-CuS nanoparticles on breast cancer cells

Abstract In spite of a decreased rate of cancer onset, by about 33%, since 1991, it is still as dreadful and a major cause of death globally. After heart disease, cancer continues to be the second most prevalent cause of death in the US. According to the American Cancer Society, there will be around 2 million new cases of cancer identified in Americans in 2023, along with approximately 610,000 cancer-related deaths. Breast cancer will continue to be the most common invasive cancer diagnosed in women. Each year about 2.3 million women are diagnosed with breast cancer. In consideration of the severity of breast cancer, herein we designed and synthesized a multimode photothermal agent, FA-Hep-CuS, for the advancement of photothermal therapy of cancer. CuS nanoparticles deposited on heparin-conjugated folic acid (FA-Hep-CuS) were prepared by gently heating unfractionated heparin in dimethyl formamide (DMF), then adding N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC), and finally adding the aminated folic acid in DMF and stirring for four days. Further, FA-Hep was dispersed in DI water, then citrated CuS nanoparticles dispersed in DI water were added, and the mixture was stirred for 8 hours to prepare FA-Hep-CuS. Moreover, the activation of the nanoparticles by non-ionizing radiation (NIR; l= 808 nm) was also evaluated for increased anti-cancer efficiency. In MDA-MB-231 (Triple-negative or TNBC or ER⁻/PR⁻/Her2⁻) breast cancer cell lines, the cytotoxic effects of FA, CuS, and FA-Hep-CuS, as well as their ability to impede motility, have been investigated. They have also been examined to determine how they affect the expression of mesenchymal indicators and clonogenicity. All these demonstrated significant dose-dependent in-vitro cytotoxicity against MDA-MB- 231 breast cancer cells. The cell viability assay showed that the FA-CuS was more effective than FA and CuS. Activation of the nanoparticles with NIR resulted in the significantly enhanced dose-dependent inhibitory potential of the nanoparticles against the migratory properties of the aggressive TNBC cells. In agreement, the clonogenicity of the TNBC cells was also inhibited dose-dependently. We are now focusing on its inhibitory potential on the EMT markers of the TNBC cells. We further aim to investigate the effects of FA-Hep-CuS in in-vivo models of breast cancers. Citation Format: David Arreola. Cytotoxicity and motility inhibitory effect of FA-Hep-CuS nanoparticles on breast cancer cells [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-27-08.

The effect of turmeric extract (Curcuma longa) on IL-6 expression

Background: Breast cancer in Indonesia is reported to have reached 68,858 out of 396,914 new cases of cancer, with an incidence rate of 16.6% based on Globocan 2020 data. Complementary therapies are much sought after for psychological and economic reasons and have minimal side effects. Curcumin has anti-carcinogenic properties. IL-6 plays an important role in the growth and metastasis of breast cancer cells, renewal of breast cancer stem cells, and drug resistance in breast cancer stem cells. Methods: A randomized controlled trial with post-test only group design using artificial female Balb/c strain rats (Mus Musculus) with DMBA-induced mammary adenocarcinoma nodules were reported, rats were divided into four groups randomly, namely, Control (K), Treatment 1: turmeric extract dose 100mg/KgBW (P1), Treatment 2: turmeric extract dose 150mg/KgBW (P2), Treatment 3: turmeric extract dose 200mg/KgBW (P3). Variables under study were IL-6 expression. One Way Anova test, followed by the Post-hoc Test, was used to test the difference among and between groups. Results: The mean value of IL-6 expression in groups K (53,59 ± 8,37), P1 (50,66 ± 9,59), P2 (66,93 ± 9,64), P3 (64,58 ± 5,97). The Post-Hoc test showed significant differences in IL-6 expression from group K against P2 (p=0.038), group P1 against P2 (p=0.015), and P3 (p=0.040). Conclusion: Turmeric extract (Curcuma longa) had an effect on IL-6 expression in the control group and the treatment group.

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

This article presents global cancer statistics by world region for the year 2022 based on updated estimates from the International Agency for Research on Cancer (IARC). There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers globally), followed by cancers of the female breast (11.6%), colorectum (9.6%), prostate (7.3%), and stomach (4.9%). Lung cancer was also the leading cause of cancer death, with an estimated 1.8 million deaths (18.7%), followed by colorectal (9.3%), liver (7.8%), female breast (6.9%), and stomach (6.8%) cancers. Breast cancer and lung cancer were the most frequent cancers in women and men, respectively (both cases and deaths). Incidence rates (including NMSC) varied from four-fold to five-fold across world regions, from over 500 in Australia/New Zealand (507.9 per 100,000) to under 100 in Western Africa (97.1 per 100,000) among men, and from over 400 in Australia/New Zealand (410.5 per 100,000) to close to 100 in South-Central Asia (103.3 per 100,000) among women. The authors examine the geographic variability across 20 world regions for the 10 leading cancer types, discussing recent trends, the underlying determinants, and the prospects for global cancer prevention and control. With demographics-based predictions indicating that the number of new cases of cancer will reach 35 million by 2050, investments in prevention, including the targeting of key risk factors for cancer (including smoking, overweight and obesity, and infection), could avert millions of future cancer diagnoses and save many lives worldwide, bringing huge economic as well as societal dividends to countries over the forthcoming decades.

Occurrence of Carcinogens and their Potential Effects on Human Health – A Review

The significant rise in cancer incidence and related deaths makes cancer one of the biggest threats to public health. Each year, there are about 10 million new cases of cancer and 6 million resultant deaths. In compliance with the disease triangle, the etiology of human cancer can be successfully traced to different environmental sources. Humans are continuously exposed to a wide range of different cancer-causing agents called carcinogens, such as household cleaners, solvents, pesticides, food additives, polluted air or environment, and other products. The Classification of Human Cancer by the International Agency for Research on Cancer (IARC) Monograph series was used as the primary data source for this review. We listed the cancer sites related to each agent based on the IARC review. Sources of these carcinogens were further grouped into classes in the IARC monograph. Home chemicals, environmental pollutants, occupational environments, environmental or medical radioactivity, drugs, microorganisms, contaminated air, and nutritional and behavioral choices are the sources of human exposure to carcinogens. The degree and frequency of exposure to carcinogens have a significant impact on their ability to cause cancer. The knowledge of carcinogens is crucial to creating awareness of cancer and advising the masses to reduce exposure to some environmental substances that are liable to cause cancer.

Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta-analysis.

To evaluate the effect of metformin on cancer incidence in subjects with overweight/obesity and/or prediabetes/diabetes. We searched MEDLINE, Embase and CENTRAL for randomized controlled trials (RCTs) in adults with overweight/obesity and/or prediabetes/diabetes that compared metformin to other interventions for ≥24 weeks. Independent reviewers selected and extracted data including population and intervention characteristics and new diagnoses of cancer. We used the RoB 2.0 risk-of-bias tool and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework to assess risk of bias and certainty of evidence. From 14 895 records after removal of duplicates, 27 trials were included, providing a total of 10 717 subjects in the metformin group and 10 003 in the control group, with 170 and 208 new cases of cancer, respectively. Using a random-effects model, the relative risk was 1.07 (95% confidence interval 0.87-1.31), with similar results in subgroup analyses by study duration or effect of control intervention on weight. Risk of bias in most studies was low, and no evidence of publication bias was found. Trial sequential analysis provided evidence that the cumulative sample size was large enough to exclude a significant effect of metformin on cancer incidence. Metformin did not reduce cancer incidence in RCTs involving subjects with overweight/obesity and/or prediabetes/diabetes.

Knowledge of Cervical Cancer and Attitude Toward Cervical Cancer Screening Among the First-Year School of Midwifery Students in FMC Nguru, North-Eastern Nigeria

Cervical cancer occurs due to Infection by high-risk human papillomavirus (HPV) and subsequent integration of the HPV genome into the host chromosome of cervical epithelial cells. The viral proto-oncogenes, mainly E6 and E7, are responsible for the initial changes in the epithelial cells of the transformation zone of the cervix. The viral proteins inactivate two main tumor suppressor proteins, p53, and retinoblastoma (pRb). Inactivation of these host proteins disrupts both the DNA repair mechanisms and apoptosis, leading to rapid cell proliferation. Cervical cancer is the 4th most common cancer among women worldwide, it ranked 14th among all cancers worldwide. There are 500,000 new cases of cancer of the cervix annually, and about 250,000 mortalities all over the world from cervical cancer. About 80% of all these cases occur in low-income countries. In Nigeria, there are 12,075 new cases of cervical cancer and 7,968 deaths due to cervical cancer per year. The study was a cross-sectional type aimed at exploring the knowledge of the participants on cancer of the cervix and their attitude toward cervical cancer screening using a semi-structured questionnaire in FMC Nguru. Results: The total number of participants was 29(n=29). The mean age of the respondents was 20.9 +/-2. 8SD. Concerning the knowledge of cervical cancer among the participants, 27(93.1%) heard of cervical cancer. Most of the respondents do not know the cause of cervical cancer, as only 10(34.5%) know that cervical cancer is associated with HPV. The risk factors for cervical Cancer are not known by most of the respondents as 14(48.3%) agreed that having a relative who had the disease is a risk factor, while only 10(34.5%) agreed that HPV is a cause of the pathology. There was poor knowledge regarding the presentation of cancer of the cervix, abnormal vaginal bleeding is the most popular way of presentation known by 13(44.8%) of the respondents while only 8(27.6%) know that cervical cancer can present with bleeding after sexual intercourse, five of the respondents (17.2%) showed smelling vaginal discharge as the mode of presentation, dysuria by only 2(6.9%). A good number of the participants know about cervical screening 26(89.7%). Twenty-eight respondents (96.6%) are willing to go and have themselves screened for cervical cancer if they are asked to do so, and 27(93.1%) will advise some other people to go for the screening. A good number of the respondents, 27(93.1%) are aware that cancer of the cervix can be prevented. Conclusion: The students had a good awareness of cervical cancer and cancer of the cervix screening and had a positive attitude toward having themselves screened whenever the chance was available, and also had a positive attitude toward being willing to convince other people to go for the screening, but demonstrated less knowledge on cervical cancer causes, risk factors and mode of presentation. Hence there is a window of opportunity to deliver more health education to the students and by extension to the larger population.

Molecular Mechanisms Determining Mammalian Oocyte Quality with the Treatment of Cancer Therapy.

Cancer is a global public health issue and remains one of the leading causes of death in the United States (Siegel et al. CA Cancer J Clin. 72:7-33, 2022). It is estimated in the US in 2022, about 935,000 new cases of cancer will be diagnosed in women, and the probability of developing invasive cancer is 5.8% for females younger than 50years old (Siegel et al. CA Cancer J Clin. 72:7-33, 2022). However, advances in screening programs, diagnostic methods, and therapeutic options have greatly increased the five-year survival rate in reproductive-age women with a variety of cancers. Given the clinical consequences of gonadotoxic cancer therapies, young, female cancer survivors may face compromised fertility, premature ovarian insufficiency, early-onset menopause, and endocrine dysregulation (Bedoschi et al. Future Oncol. 12:2333-44, 2016). Gonadotoxic side effects may include decreased oocyte quality within surviving follicles, loss of ovarian follicles, and impaired ovarian function. In reproductive-age women, oocyte quality is an important element for successful clinical pregnancies and healthy offspring as poor-quality oocytes may be a cause of infertility (McClam et al. Biol Reprod. 106:328-37, 2022; Marteil et al. Reprod Biol. 9:203-24, 2009; Krisher. J Anim Sci. 82: E14-E23, 2004). Thus, it is critical to determine the quantity and quality of surviving follicles in the ovary after cancer treatment and to assess oocyte quality within those surviving follicles as these are markers for determining the capacity for ovarian function restoration and future fertility, especially for young cancer survivors (Xu et al. Nat Med. 17:1562-3, 2011). The long-term effects of cancer therapeutics on oocyte quality are influenced by factors including, but not limited to, individual patient characteristics (e.g. age, health history, comorbidities, etc.), disease type, or treatment regimen (Marci et al. Reprod Biol Endocrinol. 16:1-112, 2018). These effects may translate clinically into an impaired production of viable oocytes and compromised fertility (Garutti et al. ESMO Open. 6:100276, 2021).

Surgical Management of Metastatic Spine Fracture

Abstract The spine is a very frequent site of metastasis from solid tumors. World Health Organisation estimated an exponential increase of 29.4 million new cases of cancer in 2040. The incidence of solid tumors metastasizing to the spinal column is from the breast, prostate, kidney, and lung. The need for treatment lies in different factors, and proper evaluation of the disease requires a “multidisciplinary team” approach. The MDT contains tumor surgery, oncology medicine, tumor radiotherapy, radiology, and pathology departments.

Telomerase: a nexus between cancer nanotherapy and circadian rhythm.

Cancer represents a complex disease category defined by the unregulated proliferation and dissemination of anomalous cells within the human body. According to the GLOBOCAN 2020 report, the year 2020 witnessed the diagnosis of approximately 19.3 million new cases of cancer and 10.0 million individuals succumbed to the disease. A typical cell eventually becomes cancerous because of a long-term buildup of genetic instability and replicative immortality. Telomerase is a crucial regulator of cancer progression as it induces replicative immortality. In cancer cells, telomerase inhibits apoptosis by elongating the length of the telomeric region, which usually protects the genome from shortening. Many nanoparticles are documented as being available for detecting the presence of telomerase, and many were used as delivery systems to transport drugs. Furthermore, telomere homeostasis is regulated by the circadian time-keeping machinery, leading to 24-hour rhythms in telomerase activity and TERT mRNA expression in mammals. This review provides a comprehensive discussion of various kinds of nanoparticles used in telomerase detection, inhibition, and multiple drug-related pathways, as well as enlightens an imperative association between circadian rhythm and telomerase activity from the perspective of nanoparticle-based anticancer therapeutics.

A statistical fuzzy clustering approach to analyze the characteristics of the number of new cancer cases in Asia for Health

Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in an organ of the human body. Asia is the continent that has the most significant number of new cases of cancer, with a percentage of 49.3% of the number of cancer patients in the world. Preventive action to deal with the spread of cancer is the responsibility of the government to improve the quality of health in the country, so it is necessary to take action to prevent the spread of cancer and help archieve the Sustainable Development Goals (SDGs) at the third point in the field of health. One of them is by determining the characteristics of the cancer and clustering countries in Asia based on their characteristics. This article will discuss the clustering of countries in Asia using fuzzy clustering in the form of fuzzy k-means, fuzzy Gustafson-Kessel babushka and fuzzy k-medoids. the results obtained from the analysis show that using fuzzy k-means will have a more excellent fuzzy silhouette index value compared to fuzzy Gustafson-Kessel babushka and fuzzy k-medoids, which is 0.6313.

Digital Archiving and Preservation of Cancer Records: Case of KNH/UoN Department of Pathology

Cancer is considered to be 3rd leading killer and 2nd among non-communicable diseases in Kenya Mutinda J. (2019). Ferlay, et al (2013) noted there are about 37,000 new cases of cancer annually and annual mortality rate of 28,000. This indicates cancer records rapidly accumulate over time and more resources are needed to collect and manage cancer-related data. KNH/UoN Department of Pathology have for a long time kept their records using a paper-based system. Objective of the study was to review current record keeping system including the process of preserving, storing and retrieving cancer records and the challenges faced, develop a model to guide the archival of locally available cancer paper-records and a web based prototype to preserve and avails this information to a wide range of stakeholders. The study used descriptive research design involving 22 participants. Random sampling technique was used to select respondents among the sampled population. The intervention prototype was developed using the RAD methodology. It was noted that cancer patient data were captured through standard forms/books (86% of the respondents) and stored in standard forms/books (71% of the respondents). 57% stated that identification of record and documenting was done based on LAB number. ICD 10 Coding system was not fully implemented as many forms had old coding format. 77% of the participants stated that the inability to track patient records with ease as a challenge and lack of technology in records management as a potential security bleach and damage of records. Findings presented a strong case for this research study where, upon prototype developed, there was concurrence among the respondents that the developed solution would be of significant to enhance cancer records management in the department and improving the healthcare service delivery process. This model can also be used to preserve other similar medical paper documents.

Chronic Myeloid Leukemia in Adolescents and Young Adults: A SEER-Based Analysis of Characteristics and Survival Outcomes of 1565 Patients

Introduction: Adolescents and Young Adults (AYA) are individuals between 15-39 years old. There are an estimated 1 million new cases of cancers in this age group yearly [1]. Although Chronic Myeloid Leukemia (CML) is typically a disease of middle-aged and elder patients, with a median age of 62 years [1], AYA accounts for about 22.1% of all CML cases [2]. There has been little focus directed towards this age group and most studies focus on the middle-aged and elderly. Despite the remarkable improvement in the survival of CML over the years, the largest study to date [3] suggested poor survival outcomes for patients in underserved populations and with low income. We aimed to determine whether sociodemographic differences exist in the AYA age group. Method: The Surveillance, Epidemiology, and End-Result (SEER) registry research plus database 17 (2000 -2020) was used to assess and compare the survival outcomes in the AYA group and older population diagnosed with CML. Both univariate and multivariate analyses were performed. Cox proportional hazards regression was used to determine prognostic factors for survival. A two-sided p-value ≤0.05 was considered significant. Results: A total of 6,319 patients with CML were identified, of which 75.2% (n= 4754) were adults ≥40 years, and 24.8% (n= 1565) were AYAs . Amongst the AYA, 51.4% (n=804) were Non-Hispanic White (NHW), 25 % (n=390) were Hispanics, 12.1% (n=189) were Non-Hispanic Black (NHB), 10.5% (n=164) were Non-Hispanic Asian or Pacific Islander (NHAPI) and 1.2% (n=18) were Non-Hispanic American Indian/Alaska Native (NHAIA) [Table 1]. The frequency of Hispanics in the AYA group was more compared to adults ≥40 years (25% vs 12.9%). NHWs had a lower frequency in the AYA group compared to adults ≥40 years (51.4% vs 67.5%) and NHBs had a similar distribution in both age groups (12.1% vs 11.6%). The proportion of mortality attributed to CML was lower in the AYA group compared to older adults ≥40 years (7.7% vs 11.9%). The results for individual Cox regression for each racial group show that AYA Hispanic males had a worse prognosis than females (HR= 2.930, 95% CI: 1.234-6.960), such observation was not seen in other AYA races [Table 2] but it was seen in Hispanic adult males ≥40 years (HR= 1.583, 95% CI: 1.074-2.334). Also, we identified that for patients aged ≥40 years, male sex was an independent poor prognostic factor for NHW (HR= 1.259, 95% CI: 1.074-1.476) and NWB (HR=1.879, 95% CI: 1.232-2.864) [Table 2]. Conclusion: Our study shows similar demographic characteristics between AYA and adults ≥40 years old. However, AYAs are less likely to die from CML compared to adults ≥40 years. Hispanic males appear to have a worse outcome than females, an observation seen in both age groups, and is independent of other analyzed prognostic factors. More research is needed to examine and identify other prognostic factors of CML in AYA with the aim of improving their survival outcomes.

Overview of Cancers and Impact of Music Therapy in Intervention: A Literature Review

Cancer is taken under consideration as a fatal disease. It’s caused by a spread of things including unhealthy lifestyles, pollution, stress, radiation exposure, infection, tobacco consumption, and unhealthy food choices. There are several varieties of cancer that affect the chassis and their growth varies depending on the type. Cancer could be a major reason for death after a heart condition. There are 10 million new cases of cancer and approximately 5 million deaths in 2020 were caused by cancer (World Health Organization, 2018)1, and deaths from cancer worldwide are projected to still rise to over 20 million by 2025 (Stewart and Wild. 2014)2. There are several intervention modes to treat cancer patients. Besides medical intervention, there are prominent psychosocial concerns that have a very noticeable impact on intervention in the case of cancer patients. Cancer treatment facilities in India have incorporated psychosocial services into cancer care by routinely assessing patients’ levels of distress. For that Music therapy can improve their quality of life by addressing the emotional, spiritual, and physical needs that will arise during this point. Furthermore, music therapy also can be applied to assist relationships throughout the grieving process by providing comfort, continuity, and opportunities for specific feelings of loss (Rossetti et al., 2017)3. Hence, there’s a greater need and justification for exploring the scope of using music therapy with cancer patients, especially in low-income countries, including India

Cancer of colon, rectum and anus: the rising burden of disease worldwide from 1990 to 2019.

Previous studies suggest that trends of cancer of colon, rectum and anus (CRA) incidence and mortality have been decreasing in recent decades. However, the trends are not uniform across age groups. This study aimed to assess the trends of the cancer of CRA burden worldwide. A descriptive study was carried out with a joinpoint regression analysis using the database of the Global Burden of Disease study. About 2.2 million new cases of cancer of CRA were diagnosed in the world in 2019, whereby cancer of CRA caused ~1.1 million deaths. Globally, the incidence trend in both sexes together was increasing in 1990-2019, while the mortality trend was decreasing. The highest rise both in incidence and mortality was observed in the East Asia region (by 3.6% per year and by 1.4% per year, respectively) and the Andean Latin America region (by 2.7% per year and by 1.2% per year, respectively). However, of particular concern is the significant increase in the incidence (by 1.7% per year) and mortality (by 0.5% per year) from cancer of CRA in people aged 15-49. Unfavorable trends in cancer of CRA in the young require more attention in management plans.

Predisposing and Overall Effects of Reproductive Hormones on Breast Cancer: A Review.

Cancer, the second leading cause of mortality worldwide, has been the subject of extensive and quickly changing scientific study and practice. Cancer remains a mystery despite the enormous effort put into understanding the genesis of cancerous cells, the development of malignant tissues, and the process by which they propagate and recur. Cells from humans that have been recruited by cancer and, to some extent, changed into pathogenic organisms or the foundation of tumors serve as agents of destruction. Understanding cancers leads to challenging philosophical issues since they undermine and use multicellular organization processes. Cancer metastasizing cells adopt new phenotypes while discarding previous behaviors. The absence of comprehensive knowledge of this has hampered the development of therapeutics for metastatic illness. For systems-level experimental and computational metastasis modeling, integrating these complex and interconnected features continues to be a problem because metastasis has typically been studied in separate physiological compartments. Lung, breast, and prostate cancers accounted for the bulk of the 18 million new cases of cancer that were diagnosed in 2018. The most frequent cancer in women is breast cancer. Animal experimentation plays a significant role in primary and translational breast cancer research. In theory, such breast cancer models should be comparable to breast cancer in humans in terms of tumor etiology, biological behavior, pathology, and treatment response.

Assessment of barriers to optimal cancer control in adult cancer treatment centres in Cameroon.

Approximately 20,745 new cases of cancer were registered annually with 13,199 (64%) deaths in 2020 in Cameroon. Despite the increasing cancer burden, there is a paucity of reliable data that can enhance decision-making for cancer control in Cameroon. This assessment was, therefore, designed to generate data that may enable stakeholders, policymakers and funders to make data-driven decisions on cancer control. We conducted a cross-sectional survey in July 2020, which enabled us to collect data on key cancer variables from six adult cancer treatment centres in Cameroon. The key components of the assessment included case detection, service availability, human resource capacity, cost of chemotherapy and radiotherapy, the safety of chemotherapy sessions, data systems, patient education, palliative care, funding for chemotherapy and chemotherapy stock. Data were compiled and analysed using Microsoft Excel 2016. Data from four of the 6 sites show that 1,636 new cases were recorded representing an annual case detection rate of 11.8%. All the six assessed facilities offered chemotherapy services, 5/6 (83.3%) offered surgery for cancers, while just 1 (16.7%) offered radiotherapy services. In addition, none offered nuclear medicine services for cancer care and treatment. Similarly, none of the facilities had the WHO-recommended number of human resources for optimal cancer care. Overall, there were only 6 medical oncologists, 2 surgical oncologists, 3 radiation oncologists and 14 oncology nurses providing services across the 6 cancer treatment centres. Treatment services are expensive for an average national, with a complete course of chemotherapy followed by radiotherapy costing ~XAF 1,240,000 (~$2,480). None of the survey facilities had a recommended safe biosafety cabinet and clean room for the preparation of chemotherapies, rendering the preparation of chemotherapies suboptimal and hazardous. Data collection tools were manual, relatively available and very different across all the surveyed sites and the interval for data collection and transmission was collectively undefined. Optimal cancer care in adult cancer treatment centres is limited by several health systems and socio-economic factors. The identification of these barriers has enabled the formulation of action-oriented interventions, leveraging on the recently adopted national strategy for the prevention and control of cancers in the country.